Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease thalassemia
Comorbidity |iron overload
Sentences 72
PubMedID- 26114738 Efficacy of deferasirox (exjade(r)) in modulation of iron overload in patients with beta-thalassemia intermedia.
PubMedID- 22023452 Although the evidence for the benefits of iron chelation therapy to treat iron overload in patients with thalassaemia is unequivocal and well founded, its use in patients with mds remains controversial because of a lack of definitive evidence documenting its benefits (10).
PubMedID- 23868464 Cost-utility analysis of deferiprone for the treatment of beta-thalassaemia patients with chronic iron overload: a uk perspective.
PubMedID- 25616857 A number of studies have reported heterogeneity of iron distribution in subjects with iron overload due to thalassemia [3-5].
PubMedID- 25671931 Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
PubMedID- 20383704 These results imply that combining the atrial ejection force index with the transmitral-derived echocardiographic assessment is a feasible way to detect early stages of myocardial iron overload in patients with beta thalassemia major.
PubMedID- 25922644 Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: a pilot study.
PubMedID- 23460118 However, in the case of patient with primary myelofibrosis the magnetic anisotropy energy barrier differed from that in normal case and, probably, the iron core size was supposed to be slightly larger than that in both normal spleen tissue and normal human liver ferritin in contrast to well-known data for iron overload in patients with thalassemia accompanied by the iron-core size increase.
PubMedID- 24847266 iron overload in patients with beta-thalassemia major lead to alterations in the arterial structures and in the thickness of the carotid arteries (cheung et al., 2002; tantawy et al., 2009).
PubMedID- 21733147 Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
PubMedID- 22066516 Relation between nt-probnp levels, iron overload, and early stage of myocardial dysfunction in beta-thalassemia major patients.
PubMedID- 21075283 iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
PubMedID- 21382180 The value of nontransferrin-bound iron (ntbi) as an index of iron overload in patients with thalassemia has been evaluated; however, data in patients with sickle cell disease (scd) is limited.
PubMedID- 23426199 iron overload in beta-thalassemia intermedia: an emerging concern.
PubMedID- 26205801 Objectives: 'the aim of this work was to compare the efficacy of different iron chelating agents' in the treatment of ' iron overload in children with beta thalassemia major'.
PubMedID- 25820920 The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study.
PubMedID- 23834310 Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden.
PubMedID- 22933160 Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
PubMedID- 20450494 The pathophysiology of thalassaemia is associated with iron overload that generates oxygen free radicals and oxidative tissue injury with ocular vessel alterations.
PubMedID- 23026844 Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a uk perspective.
PubMedID- 23966105 Authors' conclusions: in the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate.
PubMedID- 23600689 Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the italian webthal project.

Page: 1 2